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A BS TR AC T
BACKGROUND
Recent guidance for the management of acute otorrhea in children with tympanos-
tomy tubes is based on limited evidence from trials comparing oral antibiotic 
agents with topical antibiotics.
METHODS
In this open-label, pragmatic trial, we randomly assigned 230 children, 1 to 10 years of 
age, who had acute tympanostomy-tube otorrhea to receive hydrocortisone–bacitracin–
colistin eardrops (76 children) or oral amoxicillin–clavulanate suspension (77) or to 
undergo initial observation (77). The primary outcome was the presence of otorrhea, 
as assessed otoscopically, 2 weeks after study-group assignment. Secondary outcomes 
were the duration of the initial otorrhea episode, the total number of days of otorrhea 
and the number of otorrhea recurrences during 6 months of follow-up, quality of 
life, complications, and treatment-related adverse events.
RESULTS
Antibiotic–glucocorticoid eardrops were superior to oral antibiotics and initial obser-
vation for all outcomes. At 2 weeks, 5% of children treated with antibiotic–gluco-
corticoid eardrops had otorrhea, as compared with 44% of those treated with oral 
antibiotics (risk difference, −39 percentage points; 95% confidence interval [CI], 
−51 to −26) and 55% of those treated with initial observation (risk difference, −49 
percentage points; 95% CI, −62 to −37). The median duration of the initial episode 
of otorrhea was 4 days for children treated with antibiotic–glucocorticoid eardrops 
versus 5 days for those treated with oral antibiotics (P<0.001) and 12 days for those 
who were assigned to initial observation (P<0.001). Treatment-related adverse 
events were mild, and no complications of otitis media, including local cellulitis, 
perichondritis, mastoiditis, and intracranial complications, were reported at 2 weeks.
CONCLUSIONS
Antibiotic–glucocorticoid eardrops were more effective than oral antibiotics and 
initial observation in children with tympanostomy tubes who had uncomplicated 
acute otorrhea. (Funded by the Netherlands Organization for Health Research and 
Development; Netherlands Trial Register number, NTR1481.)
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The insertion of tympanostomy tubes is one of the most frequently performed surgical procedures in children.1 The main 
indications for this procedure are the restoration 
of hearing in children with persistent otitis me-
dia with effusion and the prevention of recur-
rences in children who have recurrent acute otitis 
media.2 Acute otorrhea is a common sequela in 
children with tympanostomy tubes, with report-
ed incidence rates ranging from 26% in a meta-
analysis of mainly observational studies (involv-
ing cases of clinically manifested otorrhea) to 75% 
in a randomized trial (which included asymp-
tomatic and subclinical cases).3-5 Acute tympa-
nostomy-tube otorrhea may be accompanied by 
foul odor, pain, and fever and can reduce the 
child’s quality of life.6
Acute tympanostomy-tube otorrhea is thought 
to be the result of acute otitis media, whereby 
middle-ear fluid drains through the tube. Bacte-
rial infection or superinfection of the middle ear 
is considered to be the predominant cause of 
acute otitis media and, hence, acute tympanos-
tomy-tube otorrhea.7 Treatment is therefore aimed 
at eradicating bacterial infection, with the options 
including broad-spectrum oral antibiotics and 
antibiotic eardrops with or without glucocorti-
coids.8
The few trials comparing topical and oral anti-
biotics in children with this condition have had 
either small samples or methodologic limita-
tions.8-11 The results have indicated that anti-
biotic or antibiotic–glucocorticoid eardrops are 
as effective as, or more effective than, oral anti-
biotics. In addition, topical treatment is unlikely 
to have systemic side effects and is thought by 
some to be less likely to cause microbial resis-
tance of otopathogens than oral treatment.9,11,12 
Since acute tympanostomy-tube otorrhea, like 
acute otitis media, may be self-limiting, initial 
observation may also be a good alternative.8,13,14 
In this trial, we compared the effectiveness of 
three strategies for the management of acute 
tympanostomy-tube otorrhea in children: imme-
diate treatment with antibiotic–glucocorticoid 
eardrops, immediate treatment with oral anti-
biotics, and initial observation.
ME THODS
TRIAL CONDUCT AND OVERSIGHT
We performed an open-label, pragmatic, random-
ized, controlled trial. All the authors vouch for 
the completeness and accuracy of the data and 
analyses presented and for the fidelity of the trial 
to the study protocol. For details of the study 
design and statistical analysis plan, see the study 
protocol, available with the full text of this arti-
cle at NEJM.org. The study was approved by the 
medical ethics committee of University Medical 
Center Utrecht. There was no commercial involve-
ment in the trial.
PATIENTS
Children 1 to 10 years of age with symptoms of 
tympanostomy-tube otorrhea that had lasted for 
up to 7 days at the time of screening were eligible 
for trial participation. We excluded children with 
a body temperature of more than 38.5°C, those 
who had received antibiotics during the previous 
2 weeks, those who had had tympanostomy tubes 
placed within the previous 2 weeks, and those 
who had had an episode of otorrhea in the previ-
ous 4 weeks, three or more episodes in the pre-
vious 6 months, or four or more episodes in the 
previous year. We also excluded children with 
Down’s syndrome, a craniofacial anomaly, a 
known immunodeficiency, or an allergy to the 
medications used in this study.
PATIENT RECRUITMENT 
From June 2009 through May 2012, ear, nose, and 
throat surgeons and family physicians approached 
parents of children with tympanostomy tubes for 
study participation. Our research team contacted 
by telephone parents who expressed interest in 
participation. We informed them about the trial 
and checked inclusion and exclusion criteria. If a 
child had otorrhea at the time of the telephone 
call and was eligible for participation, a home visit 
was planned. If there were no current symptoms 
of otorrhea, parents were asked to contact the 
study center as soon as otorrhea occurred, so 
that a home visit by the study physician could be 
arranged.
BASELINE ASSESSMENTS
At the home visit, the study physician obtained 
written informed consent from parents, con-
firmed the presence of otorrhea otoscopically, 
took otorrhea samples for bacterial culture, and 
collected demographic and disease-specific data. 
Parents completed the Child Health Question-
naire (CHQ),15,16 which measures generic health-
related quality of life, and the Otitis Media–6 
(OM-6) questionnaire,17 which measures disease-
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specific health-related quality of life. Scores on 
the CHQ range from 1 to 35 across the four CHQ 
domains, with higher scores indicating better 
quality of life. Scores on the OM-6 questionnaire 
range from 6 to 42, with lower scores indicating 
better quality of life.
STUDY-GROUP ASSIGNMENTS
An independent data manager generated a ran-
domization sequence (with the use of block sizes 
of six), with stratification according to age (<4 years 
vs. ≥4 years). The study physician accessed the 
trial randomization website at the conclusion of 
the home visit to obtain the study-group assign-
ment. The randomization assignment was con-
cealed and could not be predicted in advance of 
or during enrollment. The assignments were 
balanced in a 1:1:1 ratio for the three study 
groups: hydrocortisone–bacitracin–colistin ear-
drops (Bacicoline-B, Daleco Pharma) (adminis-
tered as five drops, three times daily, in the 
discharging ear or ears for 7 days), oral amoxicil-
lin–clavulanate suspension (30 mg of amoxicillin 
and 7.5 mg of clavulanate per kilogram of body 
weight per day, divided into three daily doses ad-
ministered orally for 7 days), or initial observa-
tion for 2 weeks (no assigned medication pre-
scription to fill).
The study physician did not clean the ear ca-
nal, either at the baseline visit or at follow-up 
visits during the trial. Parents of children as-
signed to treatment with topical antibiotics were 
instructed to clean the outer ear of any dis-
charge that could easily be removed with a tissue 
before applying the drops. In addition, they were 
instructed to tilt the child’s head to one side (to 
an angle of approximately 90 degrees) when ap-
plying the eardrops and to have the child main-
tain this tilt for a few minutes to allow the drops 
to enter the ear canal. No other instructions, 
such as tragal pumping, were given. After the 
first follow-up visit, at 2 weeks, further manage-
ment of otorrhea was left to the discretion of the 
child’s ear, nose, and throat surgeon or family 
physician.
FOLLOW-UP
Parents kept a daily diary of treatment adherence, 
adverse events, and complications for 2 weeks 
and of ear-related symptoms for 6 months. At 
2 weeks and at 6 months, the study physician 
visited the child at home, performed otoscopy, 
and checked and collected the parental diaries, 
and the parents completed the generic and disease-
specific health-related quality-of-life question-
naires.
PRIMARY AND SECONDARY OUTCOMES
The primary outcome, treatment failure, was de-
fined as the presence of otorrhea in one or both 
ears, as observed otoscopically by the study phy-
sician 2 weeks after study-group assignment. 
Secondary outcomes were based on parental 
diaries and included duration of the initial otor-
rhea episode (from study-group assignment up 
to the first day of otorrhea that was followed by 
7 or more days without otorrhea), total number 
of days with otorrhea and number of recurrent 
otorrhea episodes (≥1 day with otorrhea after 
≥7 days without otorrhea) during 6 months of 
follow-up, complications, and treatment-related 
adverse events in the first 2 weeks. In addition, 
generic and disease-specific health-related qual-
ity of life was assessed at 2 weeks of follow-up.
STATISTICAL ANALYSIS
Using SPSS software, version 20 (SPSS), and 
Episheet software, October 2012 version,18 we 
performed all analyses according to the inten-
tion-to-treat principle and, except for treatment-
related adverse events, the analyses were blinded 
with respect to study-group assignment. We im-
puted missing baseline data using unconditional 
medians.19
The main comparisons in our study were 
antibiotic–glucocorticoid eardrops versus oral anti-
biotics and antibiotic–glucocorticoid eardrops 
versus initial observation. For these comparisons, 
we calculated risk differences with 95% confi-
dence intervals and numbers needed to treat in 
order to prevent one case of otorrhea at 2 weeks 
as assessed otoscopically. To control for multiple 
testing, topical treatment had to be superior in 
both comparisons. Assuming a conservative ef-
fect of approximately 60%,3,9,11,20 with a two-
sided threshold of 5% indicating statistical 
significance and with 90% statistical power, we 
estimated that 105 children would need to be 
enrolled in each group for the study to show a 
clinically relevant absolute difference of at least 
20 percentage points between groups for this 
primary outcome.
We also calculated the risk difference and 
95% confidence interval for the comparison of 
oral antibiotics with initial observation for our 
primary outcome, as well as relative risks and 
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95% confidence intervals for all treatment com-
parisons. Using log-binomial regression analyses, 
we adjusted relative risks for possible confound-
ing on the basis of a priori–defined clinically 
relevant and statistically significant differences 
in baseline characteristics.
For the secondary outcomes, we plotted 
 Kaplan–Meier curves to determine the duration 
of the initial otorrhea episode in the three study 
groups, and we used log-rank tests to test for 
differences between groups. We calculated me-
dians for the total number of days with otorrhea 
and the number of recurrent otorrhea episodes 
during 6 months of follow-up and for the 
change in the health-related quality-of-life scores 
at 2 weeks of follow-up. A change in the mean 
OM-6 score of 1.0 to 1.4 points is considered to 
constitute a moderate change, and a change of 
1.5 or more points is considered to constitute a 
large change.6,17 We evaluated differences be-
tween groups using Mann–Whitney U tests.
INTERIM ANALYSIS
After 2 years of recruitment, 150 children with 
acute tympanostomy-tube otorrhea underwent 
randomization. This number was considerably 
lower than our target of 315 children. After con-
sultation with the trial funder, the Netherlands 
Organization for Health Research and Develop-
ment, we opted for an interim analysis (not 
planned a priori) to be performed by an indepen-
dent data review committee. Committee mem-
bers were unaware of the study-group assign-
ments during the analysis and interpretation of 
the data.
The end point was defined a priori as a risk 
difference exceeding 20 percentage points. The 
end point was tested with the use of the Hay-
bittle–Peto approach (with a P value of <0.01 
considered to indicate statistical significance). 
Since safety (risk of harm) was not the reason 
for performing this interim analysis, patient en-
rollment continued. The interim analysis showed 
that the smallest risk difference for the primary 
outcome between the superior treatment and the 
other treatments was −32 percentage points (95% 
confidence interval [CI], −48 to −17; P<0.001). 
On May 21, 2012, the committee recommended 
that further recruitment to the trial be discon-
tinued, that follow-up of all 230 children included 
thus far be completed, that blinding be main-
tained during data analyses, and that the results 
be reported according to accepted standards.21,22
R ESULT S
ENROLLMENT
A total of 1133 potentially eligible children with 
tympanostomy tubes were registered for the trial; 
their parents were willing for them to participate 
in the trial in case acute tympanostomy-tube 
otorrhea developed. Parents of 886 children did 
not contact us or reported an otorrhea episode 
that did not fulfill the trial inclusion criteria 
(e.g., symptoms present for >7 days and otorrhea 
occurring within 2 weeks after tympanostomy-
tube insertion).
Home visits were scheduled for 247 children 
with acute tympanostomy-tube otorrhea. Among 
these children, 17 had a body temperature of 
38.5°C or higher or the tympanostomy tubes were 
no longer present (Fig. 1). A total of 230 children 
with acute tympanostomy-tube otorrhea were 
randomly assigned to receive antibiotic–gluco-
corticoid eardrops (76 children) or oral antibiot-
ics (77) or to undergo initial observation (77). In 
the first 2 weeks, 71 children (93%), 68 (88%), 
and 61 (79%) in the three groups, respectively, 
fully adhered to the assigned management strat-
egy (Fig. 1).
COMPLETENESS OF DATA
The primary outcome was assessed in 228 chil-
dren (99%). Parental diaries were available for 
221 children (96%). In these diaries, information 
on the presence of otorrhea was available for 
94% of all follow-up days (Fig. 1).
STUDY POPULATION
Demographic and clinical characteristics of the 
participants are provided in Table 1, and in Ta-
ble S1 in the Supplementary Appendix, available 
at NEJM.org. No clinically significant differ-
ences in baseline characteristics among the three 
study groups were observed. The indication for 
tube insertion (recurrent acute otitis media vs. 
persistent otitis media with effusion) and the 
bacteria cultured from otorrhea differed slightly 
among the groups (Table 1). The mean age of 
the children was 4.5 years, the median duration 
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of otorrhea before study entry was 3 days, and 
38 children (17%) had otorrhea in both ears at 
baseline.
PRIMARY ANALYSIS
At 2 weeks, 5% of children treated with eardrops 
had otorrhea, as compared with 44% of those 
who received oral antibiotics (risk difference, −39 
percentage points; 95% CI, −51 to −26; number 
needed to treat, 3) and 55% of those who were 
assigned to initial observation (risk difference, 
−49 percentage points; 95% CI, −62 to −37; num-
ber needed to treat, 2) (Table 2).
SECONDARY ANALYSES
At 2 weeks, children treated with oral antibiotics 
were less likely to have otorrhea than those who 
were assigned to initial observation, but this dif-
ference was not significant (risk difference, −11 
percentage points; 95% CI, −27 to 5). The relative 
230 Underwent randomization
247 Children had an episode of acute tympanostomy-tube
 otorrhea reported, with home visit
76 Were assigned to antibiotic– 
glucocorticoid eardrops
77 Were assigned to oral antibiotics
77 Were assigned to 
initial observation
76 Were included in primary analysis 77 Were included in primary analysis 75 Were included in primary analysis
71 Fully adhered to strategy
3 Stopped early
1 Received additional oral antibiotics
1 Stopped early and used oral
antibiotics
     
Data completeness
76 Were assessed by means of otos-
     copy at 2 wk
74 Returned parental diaries after
6 mo
—90% Of days had otorrhea status
filled out in available parental
diaries
Data completeness
77 Were assessed by means of otos-
     copy at 2 wk
74 Returned parental diaries after
6 mo
—95% Of days had otorrhea status
filled out in available parental 
diaries
        
Data completeness
75 Were assessed by means of otos-
     copy at 2 wk
73 Returned parental diaries after
6 mo
—95% Of days had otorrhea status 
        filled out in available parental 
diaries
68 Fully adhered to strategy
3 Stopped early
5 Received additional antibiotic
or antibiotic–glucocorticoid
eardrops
  1 Stopped early and used antibiotic
or antibiotic–glucocorticoid
eardrops
61 Fully adhered to strategy
6 Received oral antibiotics
7 Received antibiotic or antibiotic–
glucocorticoid eardrops 
  2 Received both oral antibiotics and
antibiotic or antibiotic–glucocorti-
coid eardrops
  1 Was lost to follow-up   
17 Did not undergo randomization because 
     body temperature >38.5°C or 
     tympanostomy tube no longer in place 
AUTHOR:
FIGURE:
ARTIST:
OLF:Issue date:
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Figure 1. Randomization, Adherence to Assigned Management Strategy, Data Completeness, and Inclusion in Primary 
Analysis.
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risks with adjustment for small baseline differ-
ences did not differ substantially from the crude 
relative risks, which consistently favored antibi-
otic–glucocorticoid eardrops (Table 2).
The median duration of the initial episode of 
otorrhea was 4 days for children treated with ear-
drops versus 5 days for those treated with oral 
antibiotics (P<0.001) and 12 days for those as-
signed to initial observation (P<0.001) (Table 2 
and Fig. 2). The median total number of days with 
otorrhea during 6 months of follow-up was 5 days 
for children receiving eardrops versus 13.5 days 
for those receiving oral antibiotics (P<0.001) and 
18 days for those assigned to initial observation 
(P<0.001). The median number of recurrent epi-
sodes of otorrhea during 6 months of follow-up 
was 0 episodes for children treated with anti-
biotic eardrops versus 1 for those treated with 
oral antibiotics (P = 0.03) and 1 for those assigned 
to initial observation (P = 0.26).
Table 1. Baseline Characteristics of Children with Acute Tympanostomy-Tube Otorrhea, According to Assigned 
Management Strategy.*
Characteristic
Antibiotic–
Glucocorticoid 
Eardrops
(N = 76)
Oral 
Antibiotics  
(N = 77)
Initial 
Observation  
(N = 77)
All Children
(N = 230)
Age — yr 4.6±2.1 4.4±2.0 4.4±2.0 4.5±2.0
Male sex — no. (%) 50 (66) 40 (52) 43 (56) 133 (58)
Duration of otorrhea before enrollment — days
Median 3 2 2 3
Range 0–7 0–7 0–7 0–7
Otorrhea in both ears — no. (%) 14 (18) 11 (14) 13 (17) 38 (17)
No. of tympanostomy­tube insertions†
Median 1 1 1 1
Range 1–7 1–3 1–5 1–7
No. of previous episodes of tympanostomy­tube 
otorrhea‡
Median 0 0 0 0
Range 0–5 0–5 0–3 0–5
Indication for tube insertion — no. (%)
Recurrent acute otitis media 36 (47) 27 (35) 36 (47) 99 (43)
Persistent otitis media with effusion 40 (53) 50 (65) 41 (53) 131 (57)
Positive otorrhea culture — no. (%)§ 69 (91) 72 (94) 71 (92) 212 (92)
Haemophilus influenzae 31 (41) 32 (42) 31 (40) 94 (40)
Staphylococcus aureus 25 (33) 27 (35) 39 (51) 91 (40)
Pseudomonas aeruginosa 16 (21) 16 (21) 10 (13) 42 (18)
Streptococcus pneumoniae 5 (7) 5 (6) 5 (6) 15 (7)
Moraxella catarrhalis 3 (4) 2 (3) 3 (4) 8 (3)
* Plus–minus values are means ±SD. There were no significant differences between the treatment groups at baseline, except 
for the duration of otorrhea before enrollment (P = 0.04 by the Kruskal–Wallis test) and the presence of Staphylo coccus aureus 
in culture (P = 0.05 by the chi­square test). Data were missing on duration of otorrhea before enrollment for one child (1%) 
in the study group that received oral antibiotics and on number of previous episodes of tympanostomy­tube otorrhea 
for three children: one child (1%) who received oral antibiotics and two (3%) who received antibiotic–glucocorticoid 
eardrops; we imputed the characteristics with the unconditional median. Complete details of the baseline characteristics 
are provided in Table S1 in the Supplementary Appendix.
† The number of tympanostomy­tube insertions included the insertion of the current tympanostomy tubes.
‡ The number of previous episodes of tympanostomy­tube otorrhea was restricted to the number of episodes with the 
current tympanostomy tubes.
§ Multiple bacteria could be present in one sample, so percentages do not add up to 100.
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At baseline, the generic and disease-specific 
health-related quality-of-life scores indicated good 
quality of life and were similar across the groups. 
At 2 weeks of follow-up, the change in the ge-
neric health-related quality-of-life scores did not 
differ significantly among the study groups. The 
changes in the disease-specific health-related 
quality-of-life scores at 2 weeks were small but 
consistently favored eardrops (Tables S2 and S3 in 
the Supplementary Appendix).
COMPLICATIONS AND ADVERSE EVENTS
No complications of otitis media, including local 
cellulitis, perichondritis, mastoiditis, and intra-
cranial complications, were reported during the 
first 2 weeks of follow-up (Table 3). A total of 16 
children (21%) who received eardrops had pain 
or discomfort when the drops were adminis-
tered, and 2 (3%) had a local rash. Gastrointesti-
nal symptoms developed in 18 children (23%) 
who received oral antibiotics, and rash developed 
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Figure 2. Kaplan–Meier Curves for the Duration of Otorrhea after Randomization as Reported by Parents in a Diary.
Children were assessed as having or not having otorrhea according to the definition of the duration of the first epi­
sode (i.e., the interval from study­group assignment up to the first day of otorrhea that was followed by 7 or more 
days without otorrhea). Data censoring took place on day 6 for the group of children with otorrhea who received 
 antibiotic–glucocorticoid eardrops.
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in 3 (4%). During 6 months of follow-up, fewer 
children treated with eardrops had episodes of 
otorrhea that persisted for 4 weeks or more, as 
compared with those treated with oral antibiotics 
or those assigned to initial observation (Table 3).
DISCUSSION
In this pragmatic, randomized, controlled trial, 
we found that antibiotic–glucocorticoid eardrops 
were superior to oral antibiotics and to initial 
observation with respect to the primary outcome 
of otorrhea at 2 weeks, as assessed otoscopically, 
in children with tympanostomy tubes and acute 
otorrhea. Our secondary analyses support these 
findings. Approximately one in two children who 
were assigned to initial observation still had otor-
rhea at 2 weeks, and initial observation resulted 
in more days with otorrhea in the following 
months than did topical or oral antibiotics. This 
suggests that initial observation may not be an 
adequate management strategy in such children.
One previous trial compared the same man-
agement strategies — antibiotic–glucocorticoid 
eardrops, oral antibiotics, and observation — 
but as prophylaxis for infection after tympanos-
tomy-tube insertion.23 Three previous trials com-
pared eardrops with oral antibiotics in the 
treatment of children with tympanostomy-tube 
otorrhea.9-11 In two of these trials, unlike ours, 
children with otorrhea that had persisted for up 
to 3 weeks (the exact duration of otorrhea at base-
line was not reported) and those who had re-
ceived treatment before study entry were allowed 
to participate.9,11 Both studies excluded children 
with positive cultures for group A streptococci 
or Pseudomonas aeruginosa from the analyses, 
which affected the applicability of these results 
to daily practice. In the third trial, which had a 
study population that was comparable to ours, 
68 children with acute tympanostomy-tube otor-
rhea were randomly assigned to oral amoxicillin, 
ciprofloxacin eardrops, or saline rinsing of the 
ear canal.10 These investigators also found anti-
Table 3. Treatment-Related and Serious Adverse Events.*
Event
Antibiotic– 
Glucocorticoid 
Eardrops
(N = 76)
Oral 
Antibiotics 
(N = 77)
Initial 
Observation
(N = 77) Absolute Risk Difference
Antibiotic–
Glucocorticoid 
Eardrops vs. 
Initial 
Observation
Antibiotic–
Glucocorticoid 
Eardrops vs.
Oral Antibiotics
Oral Antibiotics
vs. Initial 
Observation
no. of patients with event/total no. (%) percentage points (95% confidence interval)
Adverse event within 2 wk
Local discomfort or pain during 
administration
16/75 (21) 0/77 — — 21 (12 to 30) —
Gastrointestinal discomfort 0/75 18/77 (23) — — −23 (−33 to −14) —
Rash 2/75 (3) 3/77 (4) — — −1 (7 to −4) —
Oral candidiasis 0/75 0/77 — — 0 (—) —
Adverse event within 6 mo
Otorrhea episode lasting ≥4 wk 1/74 (1) 5/74 (7) 12/73 (16) −15 (−24 to −6) −5 (−12 to 1) −10 (−20 to 1)
Otorrhea episode lasting ≥12 wk 0/74 0/74 1/73 (1) −1 (−4 to 1) 0 (—) −1 (−4 to 1)
Serious adverse event within 2 wk† 0/75 0/77 0/75 — — —
* Adverse events and serious adverse events occurring within 2 weeks after study­group assignment were reported by parents in a diary in which 
data related to the treatment strategy and complications of otitis media were collected, whereas those occurring within 6 months after study­
group assignment were derived from the parental diary on ear­related symptoms. No rounding was used in the difference calculations.
† Serious adverse events included complications of otitis media, such as local cellulitis, perichondritis, mastoiditis, and intracranial complication.
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biotic eardrops to be superior to the other treat-
ments, but treatment-failure rates were higher 
than those we observed. The lower rates with 
topical treatment in our study may be explained 
by our use of eardrops containing both antibi-
otics and glucocorticoids and by our assessment 
of the treatment effect at 2 weeks rather than at 
1 week.24
A Finnish trial comparing the effectiveness of 
oral antibiotics with placebo in children with 
acute tympanostomy-tube otorrhea showed a 
shorter duration of otorrhea in children treated 
with oral antibiotics.20 During the study, the ear 
canal in participating children was cleaned by 
means of daily suction. Apart from uncertainty 
about the benefits of this additional daily inter-
vention, the study results may not be applicable 
to daily clinical practice, in which it is neither 
accepted nor practical to perform daily suction. 
We did not find that oral antibiotics provided a 
greater benefit than initial observation with re-
spect to the presence of otorrhea at 2 weeks, as 
assessed otoscopically, but we did find that the 
duration of the initial episode of otorrhea was 
shorter in children treated with oral antibiotics 
than in those assigned to initial observation.
Some aspects of our trial warrant further at-
tention. First, the antibiotic–glucocorticoid ear-
drops we used are not routinely available outside 
the Netherlands and France. We chose hydrocor-
tisone–bacitracin–colistin eardrops because they 
were the most widely used, commercially avail-
able eardrops for acute tympanostomy-tube 
otorrhea in the Netherlands that did not contain 
a potentially ototoxic aminoglycoside. The ear-
drops are active against most isolates of bacteria 
that cause acute tympanostomy-tube otorrhea 
(i.e., Streptococcus pneumoniae, Haemophilus inf luen-
zae, Moraxella catarrhalis, Staphylococcus aureus, and 
P. aeruginosa). Although evidence is lacking, we 
believe that any combination of antibiotic–gluco-
corticoid eardrops with similar antimicrobial 
activity, such as ciprofloxacin and dexametha-
sone, would be likely to have similar results.25
Second, the dose of the amoxicillin–clavula-
nate suspension that we used in our trial (30 mg 
of amoxicillin and 7.5 mg of clavulanate per kilo-
gram per day) is the recommended dose in the 
Netherlands and in other European countries 
where antimicrobial resistance rates are 
low.10,20,26,27 Third, we used a pragmatic, non-
blinded trial design to enhance the applicability 
of our findings to daily practice.28 Nevertheless, 
the outcomes assessed by the study physician 
were consistent with those reported by the par-
ents in the diaries. Fourth, we believe that these 
diary data are accurate. We collected diaries, 
including information on the presence of otor-
rhea per follow-up day, for nearly all the children. 
In a study that was parallel to this trial, we found 
a high level of agreement between parents and 
physicians in the assessment of ear discharge in 
children after management of otorrhea.29
Fifth, at the design stage of this trial, we 
assumed an absolute reduction of 20 percent-
age points in the incidence of otorrhea after 
2 weeks for one management strategy as com-
pared with the others to be clinically relevant. 
The observed risk difference was actually twice 
as large, showing the importance of our find-
ings for clinical practice. Finally, in a compari-
son of the children who were included in the 
trial with those who were not, we found simi-
larities with regard to age, sex, and number of 
previous tympanostomy-tube insertions. Since 
the design of our trial allowed the inclusion of 
children who would be treated across health 
care settings, we believe our findings are ap-
plicable to children with uncomplicated acute 
tympanostomy-tube otorrhea presenting in either 
primary or secondary care.
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